In a family of 15 people in northern Italy, six developed late-onset Alzheimer’s disease – and when researchers ran genetic tests, all six had a rare mutation in a protein-coding gene known as ...

R136S, or the “Christchurch mutation,” appears to protect against Alzheimer’s disease by suppressing inflammatory signaling ...

A recent research finding adds to evidence that brain inflammation is a major driver of neurodegenerative disorders such as ...

"Our data predicts that a 12% shift in Aβ profile could delay the age of onset in familial Alzheimer's disease by up to 5 years," says Prof. Lucía Chávez Gutiérrez.

In 1982, neurologist Francisco Lopera and his colleagues at the University of Antioquia in Medellín, Colombia, began studying a family for whom Alzheimer’s disease was a fact of life. Members ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of developing symptoms was cut in half, according to a new srudy.

A long-term trial has found that a discontinued drug halved the onset of a genetic form Alzheimer's, from all but 100% to 50%. Buoyed by the results, scientists are now trialing anti-amyloid ...

ST. LOUIS – Researchers at Washington University in St. Louis are making potential findings in delaying the onset of Alzheimer’s symptoms according to a study released last month. This study ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study. The ...

She has the most common fatal genetic disease in the U.S., which afflicts 40,000 Americans. But her case is caused by a rare genetic mutation, so medications that work for 90% of people with ...

In a family of 15 people in northern Italy, six developed late-onset Alzheimer’s disease – and when researchers ran genetic tests, all six had a rare mutation in a protein-coding gene known as ...